Agreement with Evox Therapeutics supports the utility of CAP® technology in the production of exosomes. Exosomes offer distinct advantages as highly effective drug carriers.Evox Therapeutics intends to develop CAP®-derived exosomes for several disease areas and indications
Cologne, Germany, April 16, 2020 - CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing ofa license agreement with Evox Therapeutics, Ltd. (Evox) for the development andcommercialization of therapeutic exosomes using CEVEC's proprietary CAP(R)technology.
The license agreement is the result of an ongoing collaborationbetween Evox and CEVEC which has demonstrated the utility of CEVEC's CAP(R)technology to produce exosomes. Evox intends to develop CAP(R)-derived exosomesfor several disease areas and indications. As part of the agreement, CEVEC willbe eligible for milestone payments and royalties. Further financial details ofthe agreement were not disclosed.
"We are delighted that Evox, a leader in the exosometherapeutics space, has chosen our CAP(R) cell line and technology for some oftheir exosome programs" said Dr. Nicole Faust, CEO of CEVEC. "Overthe last years, our CAP(R) cells have already shown perfect suitability for theproduction of various complex therapeutics, including recombinant proteins andviral vectors for gene therapy applications. With CAP(R) cells for exosomes, weare now enabling pharma and biotech companies to enter into a new field ofpromising therapeutic modalities and targeted drug delivery."
Evox Therapeutics is a privately held, Oxford-based biotechnologycompany focused on harnessing and engineering the natural delivery capabilitiesof extracellular vesicles, known as exosomes, to develop an entirely new classof biotherapeutics. Evox has created substantial proprietary technology tomodify exosomes using various molecular engineering, drug loading and targetingstrategies.
CAP(R) technology for exosome production for therapeutic use
Exosomes, a subgroup of extracellular vesicles composed ofcellular membranes, have been recognized as important mediators oflong-distance intercellular communication and are involved in a wide range ofbiological processes. Given their natural structure and characteristics,exosomes are highly effective drug carriers for different synthetic andbiological therapeutic agents including nucleic acids and proteins. Theirnatural ability to carry therapeutic molecules across membranes, including theblood-brain-barrier, make exosomes a promising new modality for targeted drugdelivery.
CEVEC's CAP(R) technology platform comprises a comprehensive portfolioof optimized human suspension cell lines that allows the fully scalable andefficient production for a variety of complex biomolecules including proteins,viral vectors, vaccines and exosomes. CAP(R) cells can be engineered to expressspecific macromolecules on the outer surface as well as in the inside ofexosomes. Growing in suspension in chemically defined media, CAP(R) cellsenable an easy scale-up of the production process to commercial volumes. Invarious projects, CAP(R) cells have generated high yields of very homogenoushigh-quality exosomes, verifying CEVEC's technology as an effective and safeproduction system.
CEVEC is a leading provider of high-performance cell technology for themanufacturing of advanced bio-therapeutics from R&D to manufacturing scale.The company's product portfolio comprises platform technologies for genetherapy viral vectors (AAV, Adeno, oncolytic viruses) and complex recombinantproteins.
CEVEC has developed the first stable AAV Producer Cell Line Technologywhich stably incorporates the sequences of the serotype-specific capsid and thegene of interest into the genome of the cell. The helper virus-free platformbased on suspension cells delivers a consistent quality of AAV vectors overtime due to the elimination of any transfection step.
CEVEC's CAP(R) Technology based on human suspension cellsis the ideal production platform for RCA-free adeno viral vectors, oncolyticviruses, viral vaccines and exosomes.
With CAP(R) Go CEVEC provides a solution to the increasingneed for recombinant production of complex and highly glycosylated proteinmolecules, including laminins, coagulation factors, and plasma proteins.
Formore information, please visit www.cevec.com
FollowCEVEC on LinkedIn
CEVEC Pharmaceuticals GmbH
Dr. Ulrich Kettling
Chief Business Officer
T.: +49 221 460 208 00